Technology2 platforms

We Built the Technology That Builds Our Pipelines.

Our own cell line platform addresses speed, productivity, cost and CMC risk together. What a partner takes on is not a research-stage construct but a stable, high-expressing cell line ready for transfer.

Platforms

Two platforms, developed in-house and used on our own programmes before they were offered to anyone else.

CHO-Speed™Rapid Stable Cell Line Platform: Our own rapid stable cell line platform. Transposon-based targeted gene integration yields high-titre stable pools and monoclonal lines, reaching a research cell bank (RCB) quickly.
SGTNase™In-House Transposase Variant: The engine inside CHO-Speed™. Hot-spot targeted insertion gives high integration efficiency and long-term passage stability, which keeps CDMO tech transfer smooth.

Species-specific redesign

Targets validated in humans, redesigned for companion species.

The parts that bind the target stay as they are; everything else is swapped to canine or feline sequence. Antibodies keep their CDRs while the frameworks and constant regions change; Fc-fusion proteins keep the target-binding peptide and change only the Fc. The same logic carries across all five programmes.

Human-validated antibodies and Fc-fusion proteins redesigned with canine and feline sequence, retaining the target-binding regions — Fig. 1. How human-validated antibodies and Fc-fusion proteins are caninized and felinized - the target-binding regions are retained and only the remaining domains are swapped to species sequence.

SGTNase mechanism: recognition and binding, excision, genomic integration — Fig. 2. SGTNase™ transposase recognises the ITR sequences flanking the gene-of-interest cassette, excises it from the transposon vector, and integrates it stably into the CHO genome.

CHO-Speed workflow: gene design, vector cloning, transfection with SGTNase, selection and screening, research cell bank — Fig. 3. Where SGTNase™ integration sits in the CHO-Speed™ line-generation workflow, from vector construction through to a transferable high-expressing clone.

Established Quickly, Expressed Highly, Held Stable.

High Expression
Productivity has been demonstrated in both monoclonal antibodies and fusion proteins.
Speed
The platform reaches a research cell bank (RCB) quickly, starting from gene design.
Stability
Clonal consistency and genetic stability hold over long-term passage.